For quite some time, providers, public and private payers, policy-makers, pharmacy benefit managers and patients have hoped the arrival of biosimilars would usher in a new era of competitive drug prices. However, as the U.S. market prepares to welcome its second biosimilar, Celltrion’s Inflectra, the future of biosimilars in this country remains unclear.

In his article for PM360, Barriers to Realizing Biosimilars’ Potential, Mike Kuchenreuther provides an overview of the biosimilars market and some of its uncertainties, including strategies that both biosimilar and originator manufacturers should consider for success.